Also known as cold agglutinin disease (CAD), this type of hemolytic anemia is rarer. Overall, the symptoms of warm and cold hemolytic anemia are similar and largely the same as those of anemia ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Fatty liver disease is a growing global health concern. Proglucagon-derived peptides (PGDPs), including glucagon, GLP-1, and GLP-2, are known to regulate lipid metabolism in the liver. However, the ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

with a strong clinical profile and as the only product approved for the treatment of [cold agglutinin disease], Enjaymo addresses a serious unmet medical need for patients living with this ...

Oct. 2, 2024 — Despite growing evidence of the importance of student well-being and an abundance of best practices, most institutions have yet to prioritize it as much as they do enrollment ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

If you tend to grab a sweater or blanket before others around you, you know what it’s like to always feel cold. And while all humans share a somewhat similar average body temperature ...

Almost all children get RSV at least once by the time they turn 2 years old. The common cold is an upper respiratory ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. UK to consider bill to ...

Italian pharma group Recordati (RECI.MI), opens new tab said on Friday it would buy from Sanofi (SASY.PA), opens new tab the global rights to a drug used to treat cold agglutinin disease (CAD), a ...